Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post-marketing Surveillance (Use Result Surveillance) With Refixia. A Multicentre, Non-interventional Post Marketing Surveillance of Safety and Effectiveness of Refixia in Routine Clinical Care With Haemophilia B Patients in Japan

Next Previous
Trial Profile

Post-marketing Surveillance (Use Result Surveillance) With Refixia. A Multicentre, Non-interventional Post Marketing Surveillance of Safety and Effectiveness of Refixia in Routine Clinical Care With Haemophilia B Patients in Japan

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nonacog beta pegol (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions
  • Sponsors Novo Nordisk

Most Recent Events

  • 26 Aug 2019 Status changed from not yet recruiting to recruiting.
  • 24 Jul 2019 Planned initiation date changed from 1 Jul 2019 to 31 Aug 2019.
  • 13 Jun 2019 Planned initiation date changed from 31 May 2019 to 1 Jul 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top